Tonsil cancer

Summary

Tonsil cancer (MONDO:0006998) is a cancer and 8 clinical trials. Top therapeutic interventions include trastuzumab botidotin. A subtype of Waldeyer’s ring cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tonsil cancer
Mondo ID	MONDO:0006998
EFO	EFO:1001214
MeSH	D014067
DOID	DOID:8858
ICD-10-CM	C09
ICD-11	2044833589
NCIT	C7404
SNOMED CT	363393007
UMLS	C0751560
MedGen	148341
GARD	0027770
MedDRA	10044002
Anatomy (UBERON)	UBERON:0002372
Is cancer (heuristic)	yes

Also known as: cancer of tonsil · malignant neoplasm of the tonsil · malignant neoplasm of tonsil · malignant tonsil neoplasm · malignant tonsil tumor · malignant tonsil tumour · malignant tonsillar neoplasm · malignant tonsillar tumor · malignant tonsillar tumour · malignant tumor of the tonsil · malignant tumor of tonsil · malignant tumour of the tonsil · malignant tumour of tonsil · tonsil cancer

Disease family

An umbrella term covering 4 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › Waldeyer’s ring cancer › tonsil cancer

Subtypes (4): tonsillar pillar cancer, tonsillar fossa cancer, tonsil carcinoma, tonsillar lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04277858	PHASE2	RECRUITING	Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
NCT03602079	PHASE1/PHASE2	COMPLETED	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
NCT03829033	Not specified	RECRUITING	Photon Therapy Versus Proton Therapy in Early Tonsil Cancer.
NCT06902623	Not specified	RECRUITING	Treatment De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer Receiving Definitive Radiotherapy
NCT06915038	Not specified	RECRUITING	ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
NCT03226613	Not specified	COMPLETED	New Modalities for Detection of Oropharyngeal Cancer
NCT05696314	Not specified	COMPLETED	Surgeon-performed Outpatient Transoral and Transcervical Ultrasound of the Oropharynx
NCT05698667	Not specified	COMPLETED	Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TRASTUZUMAB BOTIDOTIN	2	1
CHEMBL1510899	0	1